论文部分内容阅读
尽管铂类和紫杉醇已成为晚期卵巢癌的“金标准”方案,但因大多数患者最终仍复发而需要二线治疗方案。故要寻找一种副作用少并能延长生存期的有效药物。脂质体阿霉素(Doxil)能够克服阿霉素有关毒性:骨髓抑制、心脏毒性等。已有报道用Doxil 50 mg/m~2,每3周重复治疗耐铂耐紫杉醇卵巢癌,但临床相关性胃炎和手足综合征发生率较高。调整剂量为每4周方案后皮肤毒性的发生率下降。20％～25％的病例能持续接受这种药物。为此研究如何改良方案来减少并发症的发生。 选择组织学证实为卵巢癌、输卵管癌或原发性腹膜癌既往铂类和泰素治疗无效,有可测量病变或可根据特异性CA125标准进行研究。均接受Doxil初始剂量为40 mg/m~2,
Although platinum and paclitaxel have become the “gold standard” regimen for advanced ovarian cancer, second-line regimens are required because most patients eventually relapse eventually. Therefore, looking for an effective drug that has fewer side effects and prolongs survival. Liposomal doxorubicin (Doxil) can overcome doxorubicin-related toxicity: myelosuppression, cardiotoxicity and the like. It has been reported that with Doxil 50 mg / m ~ 2, platinum-resistant paclitaxel-resistant ovarian cancer is repeated every 3 weeks, but the incidence of clinically-related gastritis and hand-foot syndrome is high. The dose was adjusted to reduce the incidence of dermal toxicity after every 4-week regimen. 20% ~ 25% of cases continue to receive this drug. To study how to improve the program to reduce the incidence of complications. Select histology confirmed as ovarian cancer, fallopian tube cancer or primary peritoneal cancer in the past platinum and taxol treatment ineffective, measurable disease or can be based on specific CA125 standards for research. The initial dose of Doxil was 40 mg / m ~ 2,